2018-08-20 Comments Off on Orphazyme Announces Enrollment of First Patient in Phase III Clinical Trial of Arimoclomol for ALS Orphazyme Announces Enrollment of First Patient in Phase III Clinical Trial of Arimoclomol for ALS Copenhagen, August 10, 2018 – Orphazyme A/S, a biopharmaceutical company